A new trading day began on Tuesday, with Ocular Therapeutix Inc (NASDAQ: OCUL) stock price up 0.68% from the previous day of trading, before settling in for the closing price of $7.39. OCUL’s price has ranged from $4.06 to $11.77 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 123.40% over the last five years. Meanwhile, its annual earnings per share averaged -16.86%. With a float of $135.46 million, this company’s outstanding shares have now reached $156.65 million.
The firm has a total of 267 workers. Let’s measure their productivity. In terms of profitability, gross margin is 90.58%, operating margin of -230.12%, and the pretax margin is -284.02%.
Ocular Therapeutix Inc (OCUL) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Ocular Therapeutix Inc is 13.84%, while institutional ownership is 76.14%. The most recent insider transaction that took place on Feb 04 ’25, was worth 86,839. In this transaction an insider of this company sold 11,119 shares at a rate of $7.81, taking the stock ownership to the 193,444 shares. Before that another transaction happened on Jan 31 ’25, when Company’s insider sold 6,301 for $7.84, making the entire transaction worth $49,400. This insider now owns 204,563 shares in total.
Ocular Therapeutix Inc (OCUL) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -16.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -4.68% during the next five years compared to 8.38% growth over the previous five years of trading.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
Here are Ocular Therapeutix Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 12.94. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 19.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.32, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -1.07 in one year’s time.
Technical Analysis of Ocular Therapeutix Inc (OCUL)
Analysing the last 5-days average volume posted by the [Ocular Therapeutix Inc, OCUL], we can find that recorded value of 1.03 million was better than the volume posted last year of 0.93 million. As of the previous 9 days, the stock’s Stochastic %D was 18.04%. Additionally, its Average True Range was 0.40.
During the past 100 days, Ocular Therapeutix Inc’s (OCUL) raw stochastic average was set at 5.45%, which indicates a significant decrease from 22.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 37.02% in the past 14 days, which was lower than the 52.25% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.50, while its 200-day Moving Average is $8.13. Now, the first resistance to watch is $7.58. This is followed by the second major resistance level at $7.72. The third major resistance level sits at $7.92. If the price goes on to break the first support level at $7.25, it is likely to go to the next support level at $7.05. Now, if the price goes above the second support level, the third support stands at $6.91.
Ocular Therapeutix Inc (NASDAQ: OCUL) Key Stats
With a market capitalization of 1.17 billion, the company has a total of 157,217K Shares Outstanding. Currently, annual sales are 58,440 K while annual income is -80,740 K. The company’s previous quarter sales were 15,430 K while its latest quarter income was -36,490 K.
